{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:42:41Z","timestamp":1790448161084,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jval.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:02:56Z","timestamp":1487869376000},"page":"547-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Yonghong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre R.","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Bare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2017.01.006_bib1","series-title":"Breast Cancer Facts and Figures 2015\u20132016","year":"2015"},{"key":"10.1016\/j.jval.2017.01.006_bib2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","article-title":"Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2017.01.006_bib3","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jval.2017.01.006_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jval.2017.01.006_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.01.006_bib6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.6004\/jnccn.2015.0105","article-title":"Breast cancer risk reduction, version 2.2015","volume":"13","author":"Bevers","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2017.01.006_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.01.006_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.01.006_bib9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1055-9965.EPI-12-0149","article-title":"A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers","volume":"21","author":"Sigal","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2017.01.006_bib11","article-title":"NCCN clinical guidelines in oncology","year":"2015","journal-title":"Genetic\/familial high-risk assessment: breast and ovarian"},{"key":"10.1016\/j.jval.2017.01.006_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2017.01.006_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/GCO.0000000000000141","article-title":"Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment","volume":"27","author":"Kurian","year":"2015","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.jval.2017.01.006_bib14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","article-title":"Genetics of breast cancer: a topic in evolution","volume":"26","author":"Shiovitz","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib16","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","volume":"32","author":"Kurian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1524-4733.2008.00418.x","article-title":"Cost-effectiveness of testing for breast cancer susceptibility genes","volume":"12","author":"Holland","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.01.006_bib18","article-title":"Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes (BRCA1\/BRCA2)","author":"Li","year":"2011","journal-title":"2011 San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.jval.2017.01.006_bib19","first-page":"SP133","article-title":"BRCA1\/2 genetic testing found cost-effective in current era","volume":"18","author":"Goodman","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2017.01.006_bib20","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1055-9965.EPI-09-0607","article-title":"Breast cancer recurrence in older women five to ten years after diagnosis","volume":"18","author":"Bosco","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2017.01.006_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2017.01.006_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","article-title":"Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation","volume":"144","author":"Anderson","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2017.01.006_bib23","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.24200","article-title":"BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer","volume":"115","author":"Hall","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2017.01.006_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.jval.2017.01.006_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/bjs.9458","article-title":"Opportunities and challenges of next-generation DNA sequencing for breast units","volume":"101","author":"Pilgrim","year":"2014","journal-title":"Br J Surg"},{"key":"10.1016\/j.jval.2017.01.006_bib27","series-title":"SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988\u20132001, patient and tumor characteristics","author":"Ries","year":"2007"},{"key":"10.1016\/j.jval.2017.01.006_bib28","series-title":"National Vital Statistics Reports (Vol. 57, No. 1)","article-title":"United States Decennial Life Tables for 1999\u20132001, United States Life Tables","author":"Arias","year":"2008"},{"key":"10.1016\/j.jval.2017.01.006_bib29","series-title":"National Vital Statistics Reports (Vol. 64, No. 11)","article-title":"United States Life Tables, 2011","author":"Arias","year":"2015"},{"key":"10.1016\/j.jval.2017.01.006_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ajog.2013.01.026","article-title":"Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers","volume":"208","author":"Singh","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jval.2017.01.006_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO.2011.38.6060","article-title":"Online tool to guide decisions for BRCA1\/2 mutation carriers","volume":"30","author":"Kurian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib32","year":"2015","journal-title":"Clinical diagnostic laboratory fee schedule"},{"key":"10.1016\/j.jval.2017.01.006_bib33","author":"Covidien","year":"2014","journal-title":"2014 mastectomy & breast reconstruction Medicare reimbursement coding guide"},{"key":"10.1016\/j.jval.2017.01.006_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2017.01.006_bib35","series-title":"Update of Clinical Guideline 14 and 41","article-title":"Familial Breast Cancer: Full Cost Effectiveness Evidence Review and Reports (June 2013)","year":"2013"},{"key":"10.1016\/j.jval.2017.01.006_bib36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2017.01.006_bib37","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2017.01.006_bib38","unstructured":"World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). Available from: http:\/\/www.who.int\/choice\/costs\/CER_levels\/en\/#. [Accessed December 17, 2015]."},{"key":"10.1016\/j.jval.2017.01.006_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6963-9-9","article-title":"Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population","volume":"9","author":"Moore","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2017.01.006_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40291-015-0140-9","article-title":"Cost effectiveness of sequencing 34 cancer-associated genes as an aid for treatment selection in patients with metastatic melanoma","volume":"19","author":"Li","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jval.2017.01.006_bib41","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2014.59.3665","article-title":"Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis","volume":"33","author":"Gallego","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1940-6207.CAPR-10-0262","article-title":"Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population","volume":"4","author":"Dinh","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.jval.2017.01.006_bib43","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jval.2014.09.001","article-title":"Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening","volume":"17","author":"Kilambi","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.01.006_bib44","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","article-title":"Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer","volume":"22","author":"Kapoor","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2017.01.006_bib46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","article-title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis","volume":"16","author":"Cybulski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib47","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaoncol.2015.2340","article-title":"Cost-effectiveness of universal BRCA1\/2 screening: evidence-based decision making","volume":"1","author":"Long","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib48","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1001\/jama.282.22.2156","article-title":"Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness","volume":"282","author":"Kerlikowske","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2017.01.006_bib49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.1999.17.2.494","article-title":"Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2","volume":"17","author":"Grann","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2017.01.006_bib50","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJM199705153362022","article-title":"Decision analysis\u2014effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations","volume":"336","author":"Schrag","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.01.006_bib51","doi-asserted-by":"crossref","first-page":"e0136419","DOI":"10.1371\/journal.pone.0136419","article-title":"Development and validation of a next-generation sequencing assay for BRCA1 and BRCA2 variants for the clinical laboratory","volume":"10","author":"Strom","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2017.01.006_bib52","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1586\/14737140.2015.1090879","article-title":"Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer","volume":"15","author":"Lerner-Ellis","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jval.2017.01.006_bib53","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","article-title":"Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing","volume":"34","author":"Balmana","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517300669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517300669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:47:42Z","timestamp":1750006062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301517300669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1098301517300669"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2017.01.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}